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Introduction: Statin therapy is a well established treatment for hyperlipidemia. However, little 
is known about prescribing of statins for primary prevention in the real world, and even less 
about what happens to patients requiring primary prevention who are seen in a   secondary care 
setting. The purpose of this research was to investigate the appropriateness of statin   prescriptions 
by using the Joint British Society cardiovascular disease (JBS CVD) risk score for primary 
prevention in a large secondary care center.
Methods: We retrospectively analyzed 500 consecutive patients in whom a statin prescription 
was initiated over a four-month period. We excluded patients who met secondary prevention 
criteria. We used the JBS CVD risk prediction chart to calculate 10-year composite risk. We also 
studied which statins were prescribed and their starting doses.
Results: Of 500 patients consecutively started on statins in secondary care, 51 patients (10.2%) 
were treated for primary prevention. Of these, seven (14%) patients had a 10-year composite 
cardiovascular event risk of more than 20% (high-risk category), and were hence receiving 
appropriate therapy. Three main statins were prescribed for primary prevention, ie, atorvastatin 
(22 patients, 43%), simvastatin (25 patients, 49%), and pravastatin (four patients, 8%). The statins 
prescribed were initiated mainly at the 40 mg dose.
Conclusions: Statin prescribing in secondary care for primary prevention is limited to about 
10% of initiations. There is some overprescribing, because 86% of these patients did not require 
statins when risk-stratified appropriately. The majority of the prescriptions were for simvastatin 
40 mg and atorvastatin 40 mg.
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Introduction
Statin therapy is a well established treatment for hyperlipidemia. In the UK, the Joint 
British Society (JBS) has developed national guidelines on prevention of cardiovascu-
lar disease (CVD) in clinical practice. In these guidelines, the JBS has taken account 
of scientific evidence from both epidemiologic and randomized controlled studies, 
and preference has been given to evidence that is based on systematic reviews or 
meta-analyses rather than single observational studies or trials. The guidelines help 
to risk-stratify patients who will benefit most from drug therapy.1
Total CVD risk for an asymptomatic individual is estimated from several risk 
  factors, ie, age, gender, smoking habit, systolic blood pressure, and ratio of total 
cholesterol (TC) to high-density lipoprotein (HDL) cholesterol. This is expressed International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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as a probability (percentage chance) of developing CVD 
over a defined period of time, which in the JBS guideline is 
  calculated over 10 years. The logic for estimating total CVD 
risk based on major risk factors is that CVD is   multifactorial 
in origin, risk factors tend to cluster, and coexistent risk 
  factors tend to have a multiplicative effect on CVD risk.2
According to the JBS, statin therapy in the CVD risk 
range of 10%–20% is appropriate on the basis of scientific 
evidence, although absolute benefits will be small. When 
the CVD risk is ,10% over the next 10 years, the benefit of 
treatment is not established and may be too small in absolute 
terms to justify drug treatment. However, recommendations 
for a healthy lifestyle are still important.
Various primary prevention trials have used mainly 
pravastatin 20–40 mg (West Of Scotland Coronary Prevention 
Study, Antihypertensive and Lipid-Lowering Treatment to 
Prevent Heart Attack Trial [ALLHAT]), lovastatin 20–40 mg 
(Air Force/Texas Coronary Atherosclerosis Prevention 
Study), and Atorvastatin10 mg (Anglo-Scandinavian Cardiac 
Outcomes Trial-Lipid Lowering Arm [ASCOT-LLA]).3–6 
These statins at the doses mentioned earlier have similar 
clinical efficacy.7 Of note, the number needed to treat was 
250 with ALLHAT and 91 with ASCOT. The Heart Protection 
Study used simvastatin 40 mg and included patients needing 
both secondary and primary prevention.8 The proportional 
reduction in event rate was similar (and significant) in both 
groups. Recently, the Management of Elevated Cholesterol 
in the Primary Prevention Group of Adult Japanese trial of 
primary prevention showed reduction of primary events by 
33% in Japanese patients treated with low-dose pravastatin 
10–20 mg.9
Little is known about real-world prescribing in primary 
prevention, and even less about what happens to patients 
requiring primary prevention in a secondary care setting. The 
aim of this study was to investigate statin prescriptions for 
primary prevention in a large secondary care center.
Methods
We retrospectively analyzed 500 consecutive patients who 
were prescribed statins over a four-month period. We excluded 
patients who met secondary prevention   criteria. This group 
included anyone who had an acute coronary   syndrome, a cere-
brovascular event, or transient ischemic attack, and patients 
with diabetes and ischemic heart   disease. From electronic 
records and case notes, we collected data for gender, age, 
TC, HDL, blood pressure, and history of   smoking. We used 
the JBS CVD risk prediction chart to calculate the 10-year 
composite risk for each patient.
The JBS recommends intervention with lipid-lowering 
drug therapy in asymptomatic patients with known athero-
sclerotic disease, CVD risk $20% over 10 years, diabetes, 
and/or particularly elevated single risk factors.
Statin therapy is recommended for diabetic patients over 
40 years of age, those aged 18–39 years with   retinopathy, 
nephropathy, poor glycemic control (ie, glycosylated 
hemoglobin .9%), elevated blood pressure requiring anti-
hypertensive therapy, raised TC ($6.0 mmol/L), features 
of metabolic syndrome (central obesity and fasting trig-
lycerides .1.7 mmol/L [non-fasting .2.0 mmol/L], and/
or HDL cholesterol ,1.0 mmol/L in men or ,1.2 mmol/L 
in women), and/or a family history of premature CVD in a 
first-degree relative.
Patients with particularly elevated single risk factors also 
require CVD prevention. This is because they too are at high 
cardiovascular risk, regardless of the presence of other risk 
factors. This includes patients with an elevated TC/HDL cho-
lesterol ratio of $6.0 and those with familial dyslipidemia, 
such as familial hypercholesterolemia or familial combined 
hyperlipidemia.
It was assessed whether statin therapy was initiated 
according to JBS guidelines, in addition to the type of statins 
used and their starting doses.
Statistical analysis
We obtained quantitative results for initial analysis of data. 
We analyzed the data using one-way analysis of variance 
(ANOVA) statistics to calculate P values and confidence 
intervals (CI).
Results
Five hundred consecutive patients were started on statins 
in secondary care and 51 (10.2%) of these patients were 
treated for primary prevention (Figure 1). Of these, seven 
patients (14%) had a 10-year composite cardiovascular event 
risk of more than 20% (high-risk category) and hence were 
receiving appropriate therapy. No patients had significant 
hyperlipidemia requiring treatment without consulting the 
JBS charts. The basic demographic characteristics of patients 
are presented in the Table 1.
Three main statins were prescribed, ie, atorvastatin 
(22 patients, 43%), simvastatin (25 patients, 49%), and 
pravastatin (four patients, 8%). Twenty of 22 of those on 
atorvastatin were at low or medium JBS risk. Twenty of the 
25 patients who were on simvastatin were at equally low or 
medium JBS risk. Only seven patients were in the high-risk 
category, and none of these patients were on pravastatin. International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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hospital-initiated statins for primary prevention
Patients whose TC levels were .6 mmol (n = 17) received 
atorvastatin (n = 13, 76%) and simvastatin (n = 4, 24%).
Discussion
This study shows that statin prescriptions for primary preven-
tion in secondary care vary with dose and choice of statin. 
A preference for atorvastatin and simvastatin in patients whose 
TC levels were .6 mmol was identified. This prescription 
tendency may be influenced by local guidelines for second-
ary prevention (Cheshire and Merseyside Cardiac Network), 
which actually suggest a starting dose of simvastatin at 40 mg 
(baseline cholesterol #6 mmol) and of atorvastatin at 40 mg 
(baseline cholesterol $6 mmol). These variations in prescrib-
ing may occur because there is no set guidance for starting or 
maintenance doses of statins for primary prevention.
The JBS CVD risk prediction charts or similar risk 
  scoring tools should be used before initiating statins for 
primary prevention. This approach would not only identify 
the group of patients who would benefit most from statins 
but also limit side effects due to inappropriate use, and also 
have huge financial implications within the National Health 
Service. Future clinical trials to compare various statins 
and their optimum doses (also in various ethnic groups) for 
primary prevention are needed to improve the effectiveness 
of statin prescriptions for primary prevention.
Recommendations
•	 Statin therapy for primary prevention should be offered 
to patients who are at increased risk of cardiovascular 
disease
•	 The JBS CVD risk scoring system helps to risk-stratify 
asymptomatic patients who would benefit the most from 
treatment
Table 1 Baseline characteristics of patients*
Characteristics JBS risk score calculated category 
Low-risk Medium-risk High-risk
Age (years)* 51 ± 12 61 ± 10 62 ± 6
Sex
  Male 9 (45%) 12 (50%) 6 (86%)
  Female 11 (55%) 12 (50%) 1 (14%)
Systolic BP (mmhg)* 129.2 ± 18.3 140.3 ± 16.3 161.4 ± 31.4
Current smoker 2 (10%) 2 (8%) 5 (71%)
Nonsmoker 17 (85%) 22 (92%) 2 (29%)
ex-smoker 1 (5%) 0  0
TC (mmol/L)* 5.16 ± 1.4 5.57 ± 1.3 6.07 ± 1.56
hDL (mmol/L)* 1.58 ± 0.57 1.37 ± 0.37 1.20 ± 0.38
Total patients  20 24 7
Note: *Mean ± standard deviation. 
Abbreviations: TC, total cholesterol; hDL, high-density lipoprotein; BP, blood 
pressure; JBS, Joint British Society.
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Figure 1 Number of patients in each category of JBS CVD risk assessment.
The CI for mean JBS risk score was overlapping for the three 
statins used (atorvastatin 95% CI: 7.3–12.4, simvastatin 96% 
CI: 10.0–21.1, pravastatin 95% CI: 1–24). ANOVA analysis 
also did not show any significant relationship between JBS 
risk category and statin used (P = 0.252). The preferred start-
ing dose of all statins was 40 mg (n = 45), 20 mg (n = 4), 
and 10 mg (n = 2) (Figure 2). Atorvastatin 40 mg was the 
most potent and highest starting dose used for primary 
prevention.
Mean TC levels among patients prescribed all three drugs 
were similar (atorvastatin 5.9 ± 1.6, simvastatin 5.1 ± 1.2, 
pravastatin 5.2 ± 0.55, P . 0.05, Figure 3). TC levels were 
also similar for the different dosages of statins (P . 0.05). On 
further analysis of the data, we noticed that patients whose TC 
levels were #6 mmol (n = 34) received simvastatin (n = 21, 
61%), atorvastatin (n = 9, 26%), and pravastatin (n = 4, 11%). 
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Figure 2 Starting dose for primary prevention of various statins.International Journal of General Medicine
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Figure 3 TC levels (mmol/L) in three main statins used for primary prevention.
•	 Clinicians are keen to treat cholesterol to target levels; 
however, patients are not risk-stratified appropriately and 
may receive unnecessary treatment
•	 Regional guidelines for secondary prevention appear to 
influence statin prescriptions for primary prevention
•	 Clinicians appear to favor a higher starting dose of statin 
for primary prevention.
Conclusion
Only 14% of patients received statin therapy appropriately 
for primary prevention, and the rest of the prescriptions 
were issued to patients with a low to medium cardiovas-
cular composite risk score. We noticed that the choice of 
statin and dosage were not related to TC levels or JBS 
CVS risk score. However, we identified a preference 
for atorvastatin and simvastatin in patients whose TC 
levels were .6 mmol. Clinicians in hospital medicine 
preferred a higher dose of statins for primary prevention. 
We noticed an influence of secondary prevention guide-
lines in primary prevention   prescriptions, which could 
potentially lead to more side effects and noncompliance 
with statins, especially in a group of patients who are 
otherwise healthy.10
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